Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70423 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Holm Schneider und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University Hospital Erlangen, Erlangen, Germany. Hauptthemen laut MEDLINE: Isotretinoin, Dermatologic Agents. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Timber Pharmaceuticals, LEO Pharma A/S.
Abstract (Originalsprache)
Congenital ichthyoses (CI) are rare, inherited skin disorders characterized by hyperkeratosis, scaling and fissuring that significantly impair patients' quality of life. Treatment options are limited, with systemic retinoids reserved for severe cases owing to their adverse effect profile. This open‐label, single‐arm, maximal‐use trial investigated the systemic exposure and safety of a topically administered isotretinoin ointment (TMB‐001 0.05%) in patients with moderate‐to‐severe CI. Thirty‐four patients aged ≥6 years applied TMB‐001 0.05% under maximal‐use conditions (twice daily to 75%–90% of the body surface area) for 14 days, with continued application for another 10 weeks. Exposure levels for TMB‐001 0.05% and its metabolites were < 1% of those observed after single oral administration of 80 mg isotretinoin to healthy adults. A majority of patients had local safety or tolerability issues, most of which were mild. Overall, the treatment was well tolerated with no evidence of systemic toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University Hospital Erlangen, Erlangen, Germany.
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Dermatology, Venereology and Allergology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Department of Dermatology, University of Mississippi, Jackson, Mississippi, USA.
- Associated Skin Care Specialists, New Brighton, Minnesota, USA.
- Department of Dermatology, Stanford University School of Medicine, Palo Alto, California, USA.
ORCID-Profile: Holm Schneider
Förderung
- Timber Pharmaceuticals
- LEO Pharma A/S
Zitieren
APA
Schneider, H., Bunick, C. G., Hillmann, K., Huynh, T. N., Kempers, S., Peschel, N., Blume-Peytavi, U., Teng, J. M. C., Mendelsohn, A. M., Stinson, J., & Lee, L. W. (2025). Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70423
Vancouver
Schneider H, Bunick CG, Hillmann K, Huynh TN, Kempers S, Peschel N, et al. Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70423
BibTeX
@article{Schneider2025,
author = {Schneider, Holm and Bunick, Christopher G and Hillmann, Kathrin and Huynh, Thy N and Kempers, Steven and Peschel, Nicolai and Blume-Peytavi, Ulrike and Teng, Joyce M C and Mendelsohn, Alan M and Stinson, John and Lee, Lara Wine},
title = {Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70423}
}
EUVIMED